Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Feb 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain cells in the immune system, called monocytes, behave during septic shock, a serious condition caused by an infection that leads to low blood pressure and organ failure. Researchers want to understand how a specific receptor, known as the Calcium Sensing Receptor (CaSR), changes in these immune cells during septic shock. They believe that the levels of calcium in the body can become unbalanced during this condition, and they want to see if measuring the CaSR in monocytes can provide insights that might help with future treatments.

To participate in this trial, individuals must be over 18 years old and currently in the intensive care unit with septic shock. They should not have been involved in any other drug studies recently and must meet specific health criteria, such as having a certain level of lactic acid in their blood. Participants will undergo tests to measure the expression of CaSR in their monocytes, and they will provide information about their health during the study. This research could lead to new ways of treating septic shock, especially if the findings support the use of drugs that can modify calcium levels in the body.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients over the age of 18,
• • patients who have not participated in a study evaluating an investigational drug in the 30 days preceding the samples,
• • intensive care patients in a state of septic shock within the first 24 hours of the introduction of pressor amines,
• • French resident year-round,
• • lactate \> 2mmol/L,
• • patients with social security coverage.
• Exclusion Criteria:
• • Patients in hemorrhagic shock,
• • history of parathyroidectomy, patient with hypersecretion of PTHrp,
• • sarcoidosis,
• • genetic disturbance of CaSR including familial hypocalciuric hypercalcaemia,
• • current immunosuppressant treatment (anticalcineurin, mTOR inhibitor, methotrexate, high-dose corticosteroids excluding hydrocortisone and fludrocortisone),
• • chronic myelomonocytic leukemia,
• • patients with febrile neutropenia,
• • patients with acquired or constitutional immune system,
• • pregnant or breastfeeding patient,
• • patients under curators, guardianship or safeguard of justice.